Patents by Inventor William Dall'Acqua

William Dall'Acqua has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061906
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: May 26, 2020
    Publication date: March 4, 2021
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20200071423
    Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 5, 2020
    Inventors: PING TSUI, MARTIN BORROK, WILLIAM DALL'ACQUA, YANLI WU, NURTEN BEYAZ-KAVUNCU
  • Patent number: 10329345
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: June 25, 2019
    Assignee: MedImmune Limited
    Inventors: Vahe Bedian, William Dall'Acqua, Herren Wu, Michael Bowen, Jeffrey Brown, Ralph Minter, Andrew Buchanan
  • Publication number: 20190062411
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 28, 2019
    Applicant: MedImmune, LLC
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu LIN
  • Publication number: 20180273621
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: January 5, 2018
    Publication date: September 27, 2018
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20180258178
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 13, 2018
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 10011660
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 9896505
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20170267780
    Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG, constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgGI, e.g., human IgGI), that have modifications of one or more of amino acid residues in at least the CH3 domain.
    Type: Application
    Filed: May 15, 2015
    Publication date: September 21, 2017
    Inventors: PING TSUI, MARTIN BORROK, WILLIAM DALL'ACQUA, YANLI WU, NURTEN BEYAZ-KAVUNCU
  • Publication number: 20170174756
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 22, 2017
    Inventors: VAHE BEDIAN, William DALL'ACQUA, Herren WU, Michael BOWEN, Jeffrey BROWN, Ralph MINTER, Andrew BUCHANAN
  • Publication number: 20170101468
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 13, 2017
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Publication number: 20170073397
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 16, 2017
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu Lin
  • Patent number: 9562100
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 7, 2017
    Assignees: MedImmune LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Publication number: 20160145335
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 26, 2016
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20150125444
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Ping Tsui, Martin Borrok II, William Dall'Acqua
  • Publication number: 20140377181
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Patent number: 8883992
    Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Medimmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20140302058
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Applicant: MedImmune, LLC
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Patent number: 8795661
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 5, 2014
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Publication number: 20140171623
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: February 17, 2014
    Publication date: June 19, 2014
    Applicant: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet